Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | USP14 | P54578 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636233 | 0.89 | PTGDR2 (0.41) | PTGDR2 | |
| SCHEMBL4636111 | 0.88 | MAPT (0.38) | PTGS2ALDH1A1MAPTTDP1USP14 | |
| SCHEMBL3332006 | 0.86 | MAPK1 (0.43) | ALDH1A1MAPTTDP1 | |
| SCHEMBL3327671 | 0.83 | MAPT (0.33) | MAPTTDP1USP14 | |
| SCHEMBL4635997 | 0.83 | L3MBTL1 (0.40) | PTGDR2PTGS1PTGS2ALDH1A1MAPT | |
| SCHEMBL3577709 | 0.80 | MAPT (0.39) | PTGS2ALDH1A1MAPTTDP1USP14 | |
| SCHEMBL3963643 | 0.79 | PTGDR2 (0.42) | PTGDR2ALDH1A1 | |
| SCHEMBL2772075 | 0.79 | PTGDR2 (0.38) | PTGDR2PTGS1PTGS2ALDH1A1FNTA | |
| SCHEMBL3326854 | 0.79 | KMT2A (0.40) | ALDH1A1TDP1 | |
| SCHEMBL3580577 | 0.79 | ALDH1A1 (0.35) | PTGDR2ALDH1A1MAPTTDP1USP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1931663-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031747-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | HRH4, HRH2, HRH3 | PTGDR2 293/4885PTGS1 1027/4885PTGS2 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.